A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom’s macroglobulinemia
International Journal of Hematology · 2024
DOI: 10.1007/s12185-024-03761-9 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Koji Izutsu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. kizutsu@ncc.go.jp. Hauptthemen laut MEDLINE: Adenine, Antineoplastic Combined Chemotherapy Protocols, Piperidines, Rituximab. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Pharmaceutical K.K., Tokyo, Japan.
Abstract (Originalsprache)
Ibrutinib is a first-in-class Bruton kinase inhibitor against B-cell neoplasms including Waldenström macroglobulinemia (WM). This study evaluated the efficacy and safety of ibrutinib-rituximab in Japanese patients with WM. Patients received ibrutinib 420 mg orally once daily plus weekly rituximab 375 mg/m 2 IV (8 infusions total). The primary end point was major response rate (MRR; PR or better) by Independent Review Committee assessment. Secondary endpoints were progression-free survival (PFS), safety, pharmacokinetics, and biomarkers. Primary analysis was conducted in 16 patients [baseline, treatment naïve: 8 (50.0%); relapsed/refractory WM: 8 (50.0%)] who received ibrutinib-rituximab, after all patients completed Week 57 or end of treatment. At primary analysis, MRR was 87.5% [14/16 patients; 95% CI: 61.7, 98.4%; p < 0.0001 (null hypothesis: 32% response rate)]. At final analysis (median study intervention duration: 34.4 months, median follow-up: 35.0 months), MRR was unchanged at 87.5%, but VGPR [6/16 (37.5%)] and PR [8/16 (50.0%)] improved. Prior treatment status did not affect response. At final analysis, median PFS was not reached [36-month PFS rate: 86% (95% CI: 55, 96%)]. No critical safety signals were reported. This study demonstrated a positive benefit/risk profile of ibrutinib-rituximab in Japanese patients with WM, consistent with the iNNOVATE study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. kizutsu@ncc.go.jp.
- Department of Hematology and Oncology, Osaka University Hospital, Osaka, Japan.
- Division of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
- Department of Internal Medicine, Matsuyama Red Cross Hospital, Matsuyama, Japan.
- Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
- Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Förderung
- Janssen Pharmaceutical K.K., Tokyo, Japan
Zitieren
APA
Izutsu, K., Kato, H., Sekiguchi, N., Fujisaki, T., Kawakita, T., Obara, N., Matsue, K., Nishimoto, M., Hatayama, T., Inagaki, M., & Fujikawa, E. (2024). A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom’s macroglobulinemia. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03761-9
Vancouver
Izutsu K, Kato H, Sekiguchi N, Fujisaki T, Kawakita T, Obara N, et al. A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom’s macroglobulinemia. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03761-9
BibTeX
@article{Izutsu2024,
author = {Izutsu, Koji and Kato, Hisashi and Sekiguchi, Naohiro and Fujisaki, Tomoaki and Kawakita, Toshiro and Obara, Naoshi and Matsue, Kosei and Nishimoto, Mitsutaka and Hatayama, Tomoyoshi and Inagaki, Mitsuo and Fujikawa, Ei},
title = {A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom’s macroglobulinemia},
journal = {International Journal of Hematology},
year = {2024},
doi = {10.1007/s12185-024-03761-9}
}
EUVIMED